Product
Best Available Therapy
Aliases
Best Available Therapy (BAT)
Name
Best Available Therapy
7 clinical trials
10 indications
Indication
Primary MyelofibrosisIndication
Post-Polycythemia VeraIndication
MyelofibrosisIndication
Post-polycythemia Vera MyelofibrosisIndication
Primary Myelofibrosis (PMF)Indication
Polycythemia VeraIndication
Post-Essential Thrombocythemia MFIndication
Post-polycythemia Vera (Post-PV)Indication
Multiple SclerosisClinical trial
A Phase 3, Multicenter, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy (BAT) in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With RuxolitinibStatus: Active (not recruiting), Estimated PCD: 2022-12-15
Clinical trial
A Phase 2b, Open-label, Multicenter, Randomized, Controlled, 2-Arm Study to Assess the Efficacy and Safety of Orally Administered NS-018 Versus Best Available Therapy in Subjects With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)Status: Recruiting, Estimated PCD: 2024-05-24
Clinical trial
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) InhibitorStatus: Recruiting, Estimated PCD: 2026-04-27
Clinical trial
A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)Status: Recruiting, Estimated PCD: 2024-08-15
Clinical trial
A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor TreatmentStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With RuxolitinibStatus: Completed, Estimated PCD: 2016-07-28
Clinical trial
A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI)Status: Recruiting, Estimated PCD: 2026-10-01